Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:13:10.851Z.
Consensus retrieved: 2026-10-06T14:08:40.252Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:13:10.851Z.
Quote observation: 2026-10-06T16:10:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a92f25166a0617989281a7eefd332dc08894ee274fcedbd674fe1a92e2c9d78d
FORWARD PE RATIO
N/A
Satellos Bioscience Inc.
Market Cap
$10.45M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Satellos Bioscience Inc. (MSLE) | $10.45M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.54M | N/A |
| Caring Brands, Inc. (CABR)vs › | $10.68M | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.75M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $10.01M | N/A |
| Lifeward Ltd. (LFWD)vs › | $9.92M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A |
| BioVie Inc. (BIVI)vs › | $11.05M | N/A |
| Cerenome, Inc. (CNSY)vs › | $11.19M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in USD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
